Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: Similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors

64Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

We have validated an established animal model of acute inflammatory bowel disease in indomethacin-treated rats. Studies in both in vitro and in vivo 51chromium-labelled ethylenediamine tetra-acetate (51Cr-EDTA) permeability and tissue myeloperoxidase activity, a marker of inflammatory cell invasion, showed increased permeability and enzyme levels, respectively, in treated animals compared to controls (in vitro 51Cr-EDTA permeability: (mean (SE)) control 0.10 (0.02) μl/mg per tissue, experimental 0.17 (0.02) (p<0.01, 2 way analysis of variance); in vivo 51Cr-EDTA permeability: control 3.9 (1.3) (% dose recovered), experimental 12.1 (1.5) (p<0.01); tissue myeloperoxidase: control 10.8 (0.4) mU/mg, experimental 17.2 (0.5) (p<0.01). Pretreatment or simultaneous treatment of indomethacin-treated animals with glucocorticoids, sulphasalazine, or tetracycline reduced the permeability changes and the tissue inflammatory response (in vitro 51Cr-EDTA permeability: (mean (SE)) sulphasalazine+indomethacin 0.11 (0.2) μl/mg tissue (p<0.01), prednisolone±indomethacin 0.12 (0.02) (p<0.01), tetracycline+indomethacin 0.12 (0.02) (p<0.01)). Glucocorticoids and sulphasalazine, but not tetracycline, administered after the indomethacin also partially corrected the permeability and inflammatory changes induced by indomethacin (in vitro 51Cr-EDTA permeability: sulphasalazine 0.15 (0.02) μl/mg, p<0.02; prednisolone 0.12 (0.02) μl/mg, p<0.01)). This approach was used to investigate the effects of two different thromboxane synthetase inhibitors in indomethacin-treated animals. Simultaneous treatment with thromboxane synthetase inhibitors and indomethacin prevented the 51Cr-EDTA permeability and tissue myeloperoxidase increases induced by indomethacin alone (in vitro 51Cr-EDTA permeability: thromboxane synthetase inhibitors+indomethacin 0.11 (0.01) μl/mg (p<0.01); tissue myeloperoxidase: 11 (0.4) mU/mg, (p<0.01)). Thromboxane synthetase inhibitors administered after the indomethacin also partially corrected the permeability and inflammatory changes induced by indomethacin (in vitro 51Cr-EDTA permeability: thromboxane synthetase inhibitors 0.12 (0.02) mU/mg (p<0.01); tissue myeloperoxidase 13.8 (0.5) (p<0.01)). These studies indicate that thromboxane synthetase inhibitors partially correct the intestinal lesion non-steroidal anti-inflammatory drug enteropathy, and may therefore be of use in inflammatory bowel diseases in humans.

Cite

CITATION STYLE

APA

Banerjee, A. K., & Peters, T. J. (1990). Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: Similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut, 31(12), 1358–1364. https://doi.org/10.1136/gut.31.12.1358

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free